Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213306087> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3213306087 endingPage "vi40" @default.
- W3213306087 startingPage "vi40" @default.
- W3213306087 abstract "Abstract Medulloblastoma (MB) is a central nervous system (CNS) tumor that predominantly affects children and requires aggressive therapy. Affected individuals often suffer from treatment-related side-effects and treatment-resistant recurrences associated with high morbidity and mortality rates. There are four major molecular MB subgroups: wingless-type (Wnt)-activated, sonic hedgehog (Shh)-activated, group III (G3), and group IV (G4) MBs. While the molecular pathology of Wnt- and Shh-activated MBs is well defined, rather less is known about G3 and G4 MB's genetic basis, so their molecular diagnosis and consequent management have remained challenging. MBs develop through various genetic, epigenetic, and non-coding (nc)RNA-related mechanisms, with the role of ncRNAs, particularly microRNAs, in MB tumor growth is poorly defined. We addressed this knowledge gap with an exemplar of microRNA-211 (miR-211) implicated in G3 MB tumor growth. Compared to other MB subgroups, miR-211 is significantly downregulated in G3 MB cell lines, underscoring its important role as a therapeutic agent and a biomarker. miR-211 overexpression in G3 MB cells significantly reduced cell proliferation, invasion, 3D colony formation, and induced apoptosis. Oxygen consumption rates are higher in engineered cells, and we postulate that miR-211 is involved in G3 MB mitochondrial energy metabolism. miR-211 expressed G3 MB cells injected into mouse cerebella produce smaller tumors than those derived from parental cells. We applied single-cell RNA sequencing and immune histochemical assays to characterize tumors to identify the molecular mechanism of miR-211- driven tumor reduction in G3 MBs, and our preliminary results support that miR-211 is an attractive therapeutic agent to treat this aggressive MB subtype." @default.
- W3213306087 created "2021-11-22" @default.
- W3213306087 creator A5019028542 @default.
- W3213306087 creator A5035131575 @default.
- W3213306087 creator A5038084928 @default.
- W3213306087 creator A5043135433 @default.
- W3213306087 creator A5049721824 @default.
- W3213306087 creator A5056769099 @default.
- W3213306087 creator A5060115650 @default.
- W3213306087 creator A5076875996 @default.
- W3213306087 creator A5084581883 @default.
- W3213306087 date "2021-11-02" @default.
- W3213306087 modified "2023-09-27" @default.
- W3213306087 title "CSIG-32. microRNA 211, A POTENTIAL THERAPEUTIC AGENT FOR GROUP 3 MEDULLOBLASTOMA IN CHILDREN" @default.
- W3213306087 doi "https://doi.org/10.1093/neuonc/noab196.158" @default.
- W3213306087 hasPublicationYear "2021" @default.
- W3213306087 type Work @default.
- W3213306087 sameAs 3213306087 @default.
- W3213306087 citedByCount "1" @default.
- W3213306087 countsByYear W32133060872023 @default.
- W3213306087 crossrefType "journal-article" @default.
- W3213306087 hasAuthorship W3213306087A5019028542 @default.
- W3213306087 hasAuthorship W3213306087A5035131575 @default.
- W3213306087 hasAuthorship W3213306087A5038084928 @default.
- W3213306087 hasAuthorship W3213306087A5043135433 @default.
- W3213306087 hasAuthorship W3213306087A5049721824 @default.
- W3213306087 hasAuthorship W3213306087A5056769099 @default.
- W3213306087 hasAuthorship W3213306087A5060115650 @default.
- W3213306087 hasAuthorship W3213306087A5076875996 @default.
- W3213306087 hasAuthorship W3213306087A5084581883 @default.
- W3213306087 hasBestOaLocation W32133060871 @default.
- W3213306087 hasConcept C104317684 @default.
- W3213306087 hasConcept C137620995 @default.
- W3213306087 hasConcept C145059251 @default.
- W3213306087 hasConcept C190283241 @default.
- W3213306087 hasConcept C2776637008 @default.
- W3213306087 hasConcept C2780789225 @default.
- W3213306087 hasConcept C41091548 @default.
- W3213306087 hasConcept C502942594 @default.
- W3213306087 hasConcept C54355233 @default.
- W3213306087 hasConcept C62112901 @default.
- W3213306087 hasConcept C86803240 @default.
- W3213306087 hasConceptScore W3213306087C104317684 @default.
- W3213306087 hasConceptScore W3213306087C137620995 @default.
- W3213306087 hasConceptScore W3213306087C145059251 @default.
- W3213306087 hasConceptScore W3213306087C190283241 @default.
- W3213306087 hasConceptScore W3213306087C2776637008 @default.
- W3213306087 hasConceptScore W3213306087C2780789225 @default.
- W3213306087 hasConceptScore W3213306087C41091548 @default.
- W3213306087 hasConceptScore W3213306087C502942594 @default.
- W3213306087 hasConceptScore W3213306087C54355233 @default.
- W3213306087 hasConceptScore W3213306087C62112901 @default.
- W3213306087 hasConceptScore W3213306087C86803240 @default.
- W3213306087 hasIssue "Supplement_6" @default.
- W3213306087 hasLocation W32133060871 @default.
- W3213306087 hasOpenAccess W3213306087 @default.
- W3213306087 hasPrimaryLocation W32133060871 @default.
- W3213306087 hasRelatedWork W2022025167 @default.
- W3213306087 hasRelatedWork W2053446709 @default.
- W3213306087 hasRelatedWork W2339883728 @default.
- W3213306087 hasRelatedWork W2398089663 @default.
- W3213306087 hasRelatedWork W2405474943 @default.
- W3213306087 hasRelatedWork W2605887020 @default.
- W3213306087 hasRelatedWork W2735852303 @default.
- W3213306087 hasRelatedWork W2754641999 @default.
- W3213306087 hasRelatedWork W2767790526 @default.
- W3213306087 hasRelatedWork W2810269284 @default.
- W3213306087 hasVolume "23" @default.
- W3213306087 isParatext "false" @default.
- W3213306087 isRetracted "false" @default.
- W3213306087 magId "3213306087" @default.
- W3213306087 workType "article" @default.